Stay updated on Cabozantinib Combo for Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib Combo for Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Cabozantinib Combo for Renal Cell Carcinoma Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant updates, including the removal of detailed descriptions of a Phase 3 trial for cabozantinib in combination with nivolumab and ipilimumab, while retaining key information about the study's randomization and subject eligibility criteria.SummaryDifference18%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 11, 2025, while a previous date of March 25, 2025, has been removed.SummaryDifference0.3%
- Check36 days agoNo Change Detected
- Check72 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1.0%
- Check80 days agoChange DetectedThe page has updated its status to 'Active, not recruiting' and has revised several important dates related to its timeline, including the removal of past dates and the addition of future estimated dates.SummaryDifference0.7%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1.0%
Stay in the know with updates to Cabozantinib Combo for Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib Combo for Renal Cell Carcinoma Clinical Trial page.